We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer.
- Authors
Badrising, Sushil K.; van der Noort, Vincent; Hamberg, Paul; Coenen, Jules L.L.M.; aarts, Maureen J.; van Oort, Inge M.; van den Eertwegh, alfons J.M.; Los, Maartje; van den Berg, H. Pieter; Gelderblom, Hans; Vrijaldenhoven, Suzan; Kerver, Emile D.; van Voorthuizen, Theo; de Jong, Igle J.; Haanen, John B.; Bergman, andries M.
- Abstract
Objective: To evaluate the efficacy of enzalutamide (Enz) as fourth-or fifth-line treatment in men with metastasized castration-resistant prostate cancer (mCRPC), by analyzing a retrospective cohort of heavily pretreated patients. Methods: We evaluated toxicity, overall survival (OS), progression-free survival (PFS) and time to prostate-specific antigen (PSA) progression data from 47 CRPC patients treated with fourth- or fifth-line Enz. Results: All patients were treated with docetaxel and abiraterone acetate and 42 patients (89%) with cabazitaxel. The median age of the patients was 69 years (IQR, 63-73.5), 79% had bone metastases, 55% had lymph node metastases, and 17% had visceral metastases. The median duration of Enz treatment was 12.0 weeks (IQR, 8.3-20.4), and 11 patients (23%) responded to Enz (maximum PSA decline ≥50%). In general, Enz was well tolerated, with the most frequently reported adverse events being fatigue and nausea. The median OS was 40.1 weeks (95% CI, 25.4-61.4), the median PFS was 12.1 weeks (95% CI, 9.9-14.0) and the median time to PSA progression was 15.7 weeks (95% CI, 14.0-28.7). Conclusions: Analysis of this retrospective cohort suggests that Enz is well tolerated and that there is a 23% response rate in heavily pretreated CRPC patients, which is comparable with third-line treatment outcomes.
- Subjects
ANTIANDROGENS; CONFIDENCE intervals; DRUG toxicity; METASTASIS; DOCETAXEL; PROSTATE tumors; PROSTATE-specific antigen; TREATMENT effectiveness; RETROSPECTIVE studies; DESCRIPTIVE statistics; ABIRATERONE acetate; CABAZITAXEL; PROGNOSIS
- Publication
Oncology, 2016, Vol 91, Issue 5, p267
- ISSN
0030-2414
- Publication type
Article
- DOI
10.1159/000448219